Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Poignard

Showing results (31-40 of 84) with videos related to

Pageof 9
Sort By:
Immunity|September 17, 2013
Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responsesMichela Locci, Colin Havenar-Daughton, Elise Landais, et al.
Microbiology Spectrum|November 20, 2024
Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variantsLéa Dépéry, Isabelle Bally, Axelle Amen, et al.
Cell Reports|June 14, 2018
Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine DesignKimmo Rantalainen, Zachary T Berndsen, Sasha Murrell, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2011
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibodyDennis R Burton, Ann J Hessell, Brandon F Keele, et al.
Elife|February 17, 2026
Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of <i>Pseudomonas aeruginosa</i> act through distinct mechanismsJean-Mathieu Desveaux, Eric Faudry, Carlos Contreras-Martel, et al.
Journal of Virology|February 21, 2012
PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4Emilia Falkowska, Alejandra Ramos, Yu Feng, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 4, 2017
Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIVAnne-Sophie Dugast, Kelly Arnold, Giuseppe Lofano, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2011
Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaqueLaura M Walker, Devin Sok, Yoshiaki Nishimura, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 13, 2022
Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platformChristopher Chevillard, Axelle Amen, Solène Besson, et al.
Plos Pathogens|August 13, 2015
Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal AntibodiesLaura E McCoy, Emilia Falkowska, Katie J Doores, et al.
Pageof 9

Showing results (31-40 of 84) with videos related to

Sort By:
Pageof 9
Immunity|September 17, 2013
Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responsesMichela Locci, Colin Havenar-Daughton, Elise Landais, et al.
Microbiology Spectrum|November 20, 2024
Anti-SARS-CoV-2 serology based on ancestral RBD antigens does not correlate with the presence of neutralizing antibodies against Omicron variantsLéa Dépéry, Isabelle Bally, Axelle Amen, et al.
Cell Reports|June 14, 2018
Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine DesignKimmo Rantalainen, Zachary T Berndsen, Sasha Murrell, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 22, 2011
Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibodyDennis R Burton, Ann J Hessell, Brandon F Keele, et al.
Elife|February 17, 2026
Neutralizing human monoclonal antibodies that target the PcrV component of the type III secretion system of <i>Pseudomonas aeruginosa</i> act through distinct mechanismsJean-Mathieu Desveaux, Eric Faudry, Carlos Contreras-Martel, et al.
Journal of Virology|February 21, 2012
PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4Emilia Falkowska, Alejandra Ramos, Yu Feng, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 4, 2017
Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIVAnne-Sophie Dugast, Kelly Arnold, Giuseppe Lofano, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 30, 2011
Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaqueLaura M Walker, Devin Sok, Yoshiaki Nishimura, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 13, 2022
Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platformChristopher Chevillard, Axelle Amen, Solène Besson, et al.
Plos Pathogens|August 13, 2015
Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal AntibodiesLaura E McCoy, Emilia Falkowska, Katie J Doores, et al.
Pageof 9